Wellysis Corp. announced that it has issued redeemable convertible preferred stocks for gross proceeds of KRW 5,000,000,000 in a round of funding on May 30, 2022. The transaction included participation from Access Bio, Inc.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,740 KRW | +1.20% |
|
+1.05% | -24.86% |
2023 | Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc. | CI |
2023 | Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022. | CI |
1st Jan change | Capi. | |
---|---|---|
-24.86% | 166M | |
-3.07% | 8.21B | |
+7.95% | 5.77B | |
+29.16% | 5.55B | |
-16.16% | 3.83B | |
+10.30% | 2.65B | |
-64.76% | 2.36B | |
-9.60% | 2.27B | |
+21.68% | 2.11B | |
-9.05% | 1.77B |
- Stock Market
- Equities
- A950130 Stock
- News Access Bio, Inc.
- Wellysis announced that it has received KRW 5 billion in funding from Access Bio, Inc.